<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment protocols for small and large bowel cancer</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment protocols for small and large bowel cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment protocols for small and large bowel cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tim Brenner, PharmD, BCOP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shrina Duggal, PharmD, BCOP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jim Natale, PharmD, BCOP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard M Goldberg, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H15188773"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The following material represents a subset of chemotherapy and immunotherapy regimens that are used for the treatment of patients with small bowel and colorectal cancer, both in the adjuvant setting and for advanced disease. <strong>This is</strong> <strong>not an exhaustive list</strong>; it includes regimens that are considered by the authors and editors to be commonly used and important for the care of patients with bowel cancer. Additional regimens may be added over time, particularly as treatment for colorectal cancer evolves.</p><p>This topic review is intended to provide only a listing of chemotherapy and immunotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with colorectal cancer. Clinicians should refer to the individual disease-oriented topic reviews that discuss the use of these protocols in appropriate clinical situations:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15802.html" rel="external">"Systemic therapy for metastatic colorectal cancer: General principles"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2512.html" rel="external">"Therapy for metastatic colorectal cancer in older adult patients and those with a poor performance status"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2483.html" rel="external">"Potentially resectable colorectal cancer liver metastases: Integration of surgery and chemotherapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2471.html" rel="external">"Adjuvant therapy for resected stage III (node-positive) colon cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15256.html" rel="external">"Adjuvant therapy for resected stage II colon cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2529.html" rel="external">"Adjuvant therapy for resected rectal adenocarcinoma in patients not receiving neoadjuvant therapy"</a>.)</p><p></p><p>These tables are provided as examples of how to administer these regimens; there may be other acceptable methods. All chemotherapy and immunotherapy regimens must be administered by clinicians who are trained in the use of chemotherapy and immunotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</p><p>Treatment regimens for anal cancer are discussed separately. (See  <a class="medical medical_review" href="/d/html/87181.html" rel="external">"Treatment protocols for anal cancer"</a>.)</p><p class="headingAnchor" id="H15188796"><span class="h1">REGIMENS</span></p><p class="headingAnchor" id="H1223802151"><span class="h2">Chemotherapy</span></p><p class="headingAnchor" id="H15189144"><span class="h3">Short-term infusional fluorouracil and leucovorin (modified de Gramont schedule)</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef65525" href="/d/graphic/65525.html" rel="external">table 1</a>)</p><p class="headingAnchor" id="H30672543"><span class="h3">Weekly bolus fluorouracil plus high-dose leucovorin (Roswell Park Memorial Institute [RPMI] regimen)</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef86658" href="/d/graphic/86658.html" rel="external">table 2</a>)</p><p class="headingAnchor" id="H333221303"><span class="h3">Capecitabine plus bevacizumab</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef94370" href="/d/graphic/94370.html" rel="external">table 3</a>)</p><p class="headingAnchor" id="H15189229"><span class="h3">Modified FOLFOX6 (fluorouracil plus leucovorin and oxaliplatin)</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef50132" href="/d/graphic/50132.html" rel="external">table 4</a>)</p><p class="headingAnchor" id="H15189236"><span class="h3">Modified FOLFOX6 plus bevacizumab</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef62939" href="/d/graphic/62939.html" rel="external">table 5</a>)</p><p class="headingAnchor" id="H15189243"><span class="h3">Modified FOLFOX7</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef55829" href="/d/graphic/55829.html" rel="external">table 6</a>)</p><p class="headingAnchor" id="H15189250"><span class="h3">Modified FOLFOX7 plus bevacizumab</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef75802" href="/d/graphic/75802.html" rel="external">table 7</a>)</p><p class="headingAnchor" id="H510321626"><span class="h3">Capecitabine plus oxaliplatin for small intestinal adenocarcinoma</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef96117" href="/d/graphic/96117.html" rel="external">table 8</a>)</p><p class="headingAnchor" id="H932900316"><span class="h3">Capecitabine plus oxaliplatin (XELOX, CAPOX) for colorectal cancer</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef61781" href="/d/graphic/61781.html" rel="external">table 9</a>)</p><p class="headingAnchor" id="H932900341"><span class="h3">XELOX/CAPOX plus bevacizumab for colorectal cancer</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef53192" href="/d/graphic/53192.html" rel="external">table 10</a>)</p><p class="headingAnchor" id="H932900391"><span class="h3">FOLFIRI (fluorouracil plus leucovorin and irinotecan)</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef76300" href="/d/graphic/76300.html" rel="external">table 11</a>)</p><p class="headingAnchor" id="H932900416"><span class="h3">FOLFIRI plus bevacizumab</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef64505" href="/d/graphic/64505.html" rel="external">table 12</a>)</p><p class="headingAnchor" id="H932900466"><span class="h3">FOLFOXIRI (FOLFOX plus irinotecan)</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef70559" href="/d/graphic/70559.html" rel="external">table 13</a>)</p><p class="headingAnchor" id="H1902946564"><span class="h3">FOLFOXIRI plus bevacizumab for metastatic colorectal cancer</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef127023" href="/d/graphic/127023.html" rel="external">table 14</a>)</p><p class="headingAnchor" id="H3121948078"><span class="h3">Modified FOLFOXIRI plus panitumumab for colorectal cancer</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef126434" href="/d/graphic/126434.html" rel="external">table 15</a>)</p><p class="headingAnchor" id="H2312051923"><span class="h3">Neoadjuvant FOLFIRINOX (FOLFIRI plus oxaliplatin) for rectal cancer</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef134372" href="/d/graphic/134372.html" rel="external">table 16</a>)</p><p class="headingAnchor" id="H932900616"><span class="h3">Single-agent cetuximab</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef76312" href="/d/graphic/76312.html" rel="external">table 17</a>)</p><p class="headingAnchor" id="H8791457"><span class="h3">Single-agent panitumumab</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef86309" href="/d/graphic/86309.html" rel="external">table 18</a>)</p><p class="headingAnchor" id="H15188984"><span class="h3">Cetuximab plus irinotecan</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef62096" href="/d/graphic/62096.html" rel="external">table 19</a>)</p><p class="headingAnchor" id="H8791396"><span class="h3">FOLFIRI plus cetuximab</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef62726" href="/d/graphic/62726.html" rel="external">table 20</a>)</p><p class="headingAnchor" id="H8791403"><span class="h3">FOLFIRI plus panitumumab</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef86311" href="/d/graphic/86311.html" rel="external">table 21</a>)</p><p class="headingAnchor" id="H1669593808"><span class="h3">FLOX for adjuvant treatment of colon cancer</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef121667" href="/d/graphic/121667.html" rel="external">table 22</a>)</p><p class="headingAnchor" id="H3288539287"><span class="h2">Immunotherapy</span></p><p class="headingAnchor" id="H1467162173"><span class="h3">Nivolumab monotherapy for microsatellite-unstable (mismatch repair-deficient) advanced cancer</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef127100" href="/d/graphic/127100.html" rel="external">table 23</a>)</p><p class="headingAnchor" id="H514884752"><span class="h3">Pembrolizumab monotherapy for microsatellite-unstable (mismatch repair-deficient) advanced cancer</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef127101" href="/d/graphic/127101.html" rel="external">table 24</a>)</p><p class="headingAnchor" id="H1819913098"><span class="h3">Nivolumab plus ipilimumab for microsatellite-unstable (mismatch repair-deficient) metastatic colorectal cancer</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef131938" href="/d/graphic/131938.html" rel="external">table 25</a>)</p><p class="headingAnchor" id="H1942482009"><span class="h2">Concomitant chemoradiotherapy for rectal cancer</span></p><p class="headingAnchor" id="H2635971372"><span class="h3">Concomitant chemoradiotherapy with capecitabine for rectal cancer in both the adjuvant and neoadjuvant setting</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef95632" href="/d/graphic/95632.html" rel="external">table 26</a>)</p><p class="headingAnchor" id="H1646862962"><span class="h3">Concomitant chemoradiotherapy with infusional fluorouracil for rectal cancer in both the adjuvant and neoadjuvant setting</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef95677" href="/d/graphic/95677.html" rel="external">table 27</a>)</p><p class="headingAnchor" id="H29540414"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Scott M Wirth, PharmD, BCOP, who contributed to an earlier version of this topic review.</p></div><div id="topicVersionRevision">Topic 85679 Version 31.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
